Stifel raised the firm’s price target on NervGen Pharma (NGEN) to C$6.75 from C$5 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
- NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
- NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal
- NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase
- NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase